|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenues | |||||
| Rental income | |||||
| NNN | |||||
| Outpatient medical and research portfolio (OM&R) | |||||
| Total rental income | |||||
| Revenue from contracts with customers | |||||
| Resident fees and services | |||||
| Third-party capital management revenues | |||||
| Income from loans and investments | |||||
| Interest and other income | |||||
| Total revenues | |||||
| Expenses | |||||
| Interest | |||||
| Depreciation and amortization | |||||
| Property-level operating expenses | |||||
| NNN | |||||
| SHOP | |||||
| Outpatient medical and research portfolio (OM&R) | |||||
| Total property-level operating expenses | |||||
| Third-party capital management expenses | |||||
| General, administrative and professional fees | |||||
| Loss (gain) on extinguishment of debt, net | |||||
| Transaction, transition and restructuring costs | |||||
| Reversal of allowance on loans receivable and investments, net | |||||
| Gain on foreclosure of real estate | |||||
| Shareholder relations matters | |||||
| Other expense (income) | |||||
| Total expenses | |||||
| Income (loss) before unconsolidated entities, real estate dispositions, income taxes and noncontrolling interests | |||||
| Income from unconsolidated entities | |||||
| Gain on real estate dispositions | |||||
| Income tax benefit | |||||
| Net income (loss) | |||||
| Retained Earnings (Deficit) | |||||
| Total net income (loss) | |||||
| Net income attributable to noncontrolling interests | |||||
| Net income (loss) attributable to common stockholders | |||||
| Retained Earnings (Deficit) | |||||
| Total net income (loss) attributable to common stockholders | |||||
| Earnings per common share | |||||
| Basic: | |||||
| (Loss) income from continuing operations (USD per share) | |||||
| Net (loss) income attributable to common stockholders (USD per share) | |||||
| Diluted: | |||||
| (Loss) income from continuing operations (USD per share) | |||||
| Net (loss) income attributable to common stockholders (USD per share) | |||||
Loading...